BGM
TARA icon

Burkehill Global Management’s Protara Therapeutics TARA Stock Holding History

Burkehill Global Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.34M Hold
450,000
– – 0.12% 115
2025
Q4 		$2.4M Buy
+450,000
New +$2.5M 0.16% 110

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Burkehill Global Management's TARA Position: Q1 2026 in Review

Burkehill Global Management held its Protara Therapeutics (TARA) position steady in Q1 2026 at 450,000 shares worth $2.34M. The position accounts for 0.12% of the portfolio, ranked #115.

Burkehill Global Management first reported a position in TARA in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.4M in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Burkehill Global Management held 450,000 shares of Protara Therapeutics worth $2.34M as of Q1 2026.
  • Burkehill Global Management left its Protara Therapeutics share count unchanged in Q1 2026.
  • Protara Therapeutics made up 0.12% of Burkehill Global Management's portfolio in Q1 2026, its #115 holding.
  • Burkehill Global Management first reported a position in Protara Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Burkehill Global Management's Protara Therapeutics position peaked at $2.4M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.